Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Myriad Genetics hails results of ovarian cancer test

Saturday, October 8, 2016 0:25
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Myriad Genetics Inc. (NASDAQ:MYGN), the molecular diagnostics company, has hailed the results of a study of its myChoice homologous recombination deficiency (HRD) tumor test.

The company said its diagnostic product identified more than double the number of patients who may benefit from treatment with niraparib than were identified by germline BRCA testing alone. 

Germline BRCA testing can inform treatment decisions and identify women with ovarian cancer who could benefit from risk reduction strategies.

The myChoice HRD test was evaluated in the NOVA study (NCT01847274) of nirarapib, an investigational oral PARP inhibitor being developed by TESARO Inc (NASDAQ:TSRO).

Myriad’s proprietary HRD test detects when a tumor has lost the ability to repair double-stranded DNA breaks resulting in increased susceptibility to DNA-damaging drugs.

“Patients with ovarian cancer who tested positive with myChoice HRD experienced a clinically meaningful improvement in PFS [progression-free survival],” said Johnathan Lancaster, MD, PhD, gynaecological oncologist and chief medical officer of Myriad Genetic Laboratories. 

“We estimate that myChoice HRD identifies more than double the number of patients who may benefit compared to germline BRCA testing alone,”  he added.

The NOVA results showed that in patients who were germline BRCA mutation carriers, the median PFS for patients treated with niraparib was 21.0 months compared to 5.5 months for the control group.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.